公开(公告)号：US20250101103A1

公开(公告)日：2025-03-27

申请号：US18291283

申请日：2022-07-27

Applicant: MORPHOSYS AG

Inventor： Markus MOOSMEIER ,  Nicole HAUBST ,  Yvonne STARK

IPC: C07K16/28 ,  C07K16/32

Abstract: The present disclosure provides combinations or sets of two antigen binding molecule, in particular asymmetric combinations of such antigen binding molecules. Each of the two antigen binding molecules is composed of a targeting moiety with specificity for a tumor associated antigen fused to either the VL or VH domain of an antibody Fv domain specific for CD3. Once the two antigen binding molecules bind to their target antigen on the surface of a cell, the complementary VL and VH domain are capable to associate with each other thereby reconstituting the functional CD3 specific Fv domain and non-covalently dimerizing the two antigen binding molecules. The thus on-cell formed trispecific heterodimeric antibody molecule is capable of engaging and stimulating cytotoxic T-cells for tumor cell destruction.

公开(公告)号：US20230357398A1

公开(公告)日：2023-11-09

申请号：US18246052

申请日：2021-09-22

Applicant: MORPHOSYS AG

Inventor： Andreas BÜLTMANN ,  Steffen RUNZ ,  Tschimegma BATAA ,  Markus MOOSMEIER ,  Nicole HAUBST ,  Jürgen KLATTIG ,  Yvonne STARK

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/55 ,  C07K2317/31

Abstract: The present disclosure provides novel fully human antibodies and antibody fragments specific for human CD3 epsilon.